FDA Final Rule For OTC Inhaler Labeling Requires Death Warning
This article was originally published in The Tan Sheet
Executive Summary
FDA disagrees with industry comments regarding the health risks of using OTC asthma inhalers, rejecting suggested language for the final monograph covering asthma and bronchodilator drugs.